Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2020 | Alzheimer's Disease | Original Article

Three-year changes of cortical ¹⁸F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer’s disease

Authors: Matthieu Vanhoutte, Franck Semah, Xavier Leclerc, Adeline Rollin Sillaire, Alice Jaillard, Grégory Kuchcinski, Xavier Delbeuck, Rachid Fahmi, Florence Pasquier, Renaud Lopes

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2020

Abstract

Purpose

To examine and compare longitudinal changes of cortical glucose metabolism in amnestic and non-amnestic sporadic forms of early-onset Alzheimer’s disease and assess potential associations with neuropsychological performance over a 3-year period time.

Methods

Eighty-two participants meeting criteria for early-onset (< 65 years) sporadic form of probable Alzheimer’s disease and presenting with a variety of clinical phenotypes (47 amnestic and 35 non-amnestic forms) were included at baseline and followed up for 1.44 ± 1.23 years. All of the participants underwent a work-up at baseline and every year during the follow-up period, which includes clinical examination, neuropsychological testing, genotyping, cerebrospinal fluid biomarker assays, and structural MRI and ¹⁸F-FDG PET. Vertex-wise partial volume-corrected glucose metabolic maps across the entire cortical surface were generated and longitudinally assessed together with the neuropsychological scores using linear mixed-effects modeling as a function of amnestic and non-amnestic sporadic forms of early-onset Alzheimer’s disease.

Results

Similar evolution patterns of glucose metabolic decline between amnestic and non-amnestic forms were observed in widespread neocortical cortices. However, only non-amnestic forms appeared to have a greater reduction of glucose metabolism in lateral orbitofrontal and bilateral medial temporal cortices associated with more severe declines of neuropsychological performance compared with amnestic forms. Furthermore, results suggest that glucose metabolic decline in amnestic forms would progress along an anterior-to-posterior axis, whereas glucose metabolic decline in non-amnestic forms would progress along a posterior-to-anterior axis.

Conclusions

We found differences in spatial distribution and temporal trajectory of glucose metabolic decline between amnestic and non-amnestic early-onset Alzheimer’s disease groups, suggesting that one might want to consider treating the two forms of the disease as two separate entities.

Available only for authorised users

http://surfer.nmr.mgh.harvard.edu/

http://www.fil.ion.ucl.ac.uk/spm/

https://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalEdits

https://www.r-project.org

http://surfer.nmr.mgh.harvard.edu/

https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM

Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimer's Dis : JAD. 2010;19:1401–8. https://doi.org/10.3233/jad-2010-1337.CrossRef

Mendez MF. Early-onset Alzheimer’s disease: nonamnestic subtypes and type 2 AD. Arch Med Res. 2012;43:677–85. https://doi.org/10.1016/j.arcmed.2012.11.009.CrossRefPubMedPubMedCentral

Ossenkoppele R, Cohn-Sheehy BI, La Joie R, Vogel JW, Moller C, Lehmann M, et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer’s disease. Hum Brain Mapp. 2015. https://doi.org/10.1002/hbm.22927.CrossRefPubMedPubMedCentral

Phillips JS, Da Re F, Dratch L, Xie SX, Irwin DJ, McMillan CT, et al. Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer’s disease. Neurobiol Aging. 2018;63:75–87. https://doi.org/10.1016/j.neurobiolaging.2017.11.008.CrossRefPubMed

Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74:427–36. https://doi.org/10.1001/jamaneurol.2016.5755.CrossRefPubMedPubMedCentral

Phillips JS, Da Re F, Irwin DJ, McMillan CT, Vaishnavi SN, Xie SX, et al. Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer’s disease. Brain J Neurol. 2019;142:1701–22. https://doi.org/10.1093/brain/awz091.CrossRef

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed

Vanhoutte M, Semah F, Rollin Sillaire A, Jaillard A, Petyt G, Kuchcinski G, et al. 18F-FDG PET hypometabolism patterns reflect clinical heterogeneity in sporadic forms of early-onset Alzheimer’s disease. Neurobiol Aging. 2017;59:184–96. https://doi.org/10.1016/j.neurobiolaging.2017.08.009.CrossRefPubMed

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer's Dementia : the journal of the Alzheimer's Association. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.CrossRef

10.

Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis. Alzheimers Dement. 2014;10:S390–S4. e2.CrossRefPubMed

11.

Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Se C, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.CrossRefPubMedPubMedCentral

12.

Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, et al. Consensus classification of posterior cortical atrophy. Alzheimer's Dementia : the journal of the Alzheimer's Association. 2017;13:870–84. https://doi.org/10.1016/j.jalz.2017.01.014. CrossRef

13.

Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain J Neurol. 2015;138:2732–49.CrossRef

14.

Vanhoutte M, Semah F, Lopes R, Jaillard A, Petyt G, Aziz AL, et al. Using EQ.PET to reduce reconstruction-dependent variations in [<sup>18</sup>F]FDG-PET brain imaging. Phys Med Biol. 2019. https://doi.org/10.1088/1361-6560/ab35b4.

15.

Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18 F] FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103.CrossRefPubMed

16.

Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration. NeuroImage. 2009;48:63–72. https://doi.org/10.1016/j.neuroimage.2009.06.060.CrossRefPubMed

17.

Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med : official publication, Society of Nuclear Medicine. 2004;45:192–201.

18.

Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage: Clinical. 2014;6:445–54.CrossRef

19.

Küntzelmann A, Guenther T, Haberkorn U, Essig M, Giesel F, Henze R, et al. Impaired cerebral glucose metabolism in prodromal Alzheimer’s disease differs by regional intensity normalization. Neurosci Lett. 2013;534:12–7.CrossRefPubMed

20.

Reuter M, Fischl B. Avoiding asymmetry-induced bias in longitudinal image processing. NeuroImage. 2011;57:19–21.CrossRefPubMed

21.

Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage. 2012;61:1402–18.CrossRefPubMed

22.

Hughes CP, Berg L, Danziger W, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72.CrossRefPubMed

23.

Baddeley AD, Emslie H, Nimmo-Smith I. Doors and people: a test of visual and verbal recall and recognition: Thames Valley Test Company; 1994.

24.

Deloche G, Hannequin D. DO 80: Epreuve de Dénomination Orale d’images. Paris: Editions du Centre de Psychologie Appliquée; 1997.

25.

Lim CY, Tan PC, Koh C, Koh E, Guo H, Yusoff ND, et al. Beery-Buktenica Developmental Test of Visual-Motor Integration (Beery-VMI): lessons from exploration of cultural variations in visual-motor integration performance of preschoolers. Child Care Health Dev. 2015;41:213–21. https://doi.org/10.1111/cch.12190.CrossRefPubMed

26.

Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB a frontal assessment battery at bedside. Neurology. 2000;55:1621–6.CrossRefPubMed

27.

Godefroy O. Fonctions exécutives et pathologies neurologiques et psychiatriques: évaluation en pratique clinique: Groupe de Boeck; 2008.

28.

Bernal-Rusiel JL, Greve DN, Reuter M, Fischl B, Sabuncu MR, Initiative AsDN. Statistical analysis of longitudinal neuroimage data with linear mixed effects models. NeuroImage. 2013;66:249–60.CrossRefPubMed

29.

Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. NeuroImage. 2014;92:381–97. https://doi.org/10.1016/j.neuroimage.2014.01.060.CrossRefPubMed

30.

Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93:491–507.CrossRef

31.

Morey RD. Confidence intervals from normalized data: a correction to Cousineau (2005). reason. 2008;4:61–4.

32.

Frost MA, Esposito F, Goebel R. Improved correspondence of resting-state networks after macroanatomical alignment. Hum Brain Mapp. 2014;35:673–82. https://doi.org/10.1002/hbm.22191.CrossRefPubMed

33.

Hagler DJ Jr, Saygin AP, Sereno MI. Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. NeuroImage. 2006;33:1093–103. https://doi.org/10.1016/j.neuroimage.2006.07.036.CrossRefPubMed

34.

Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study. Lancet. 2003;362:1121–2.CrossRefPubMed

35.

Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18. https://doi.org/10.1016/j.neurobiolaging.2009.07.002.CrossRefPubMed

36.

Migliaccio R, Agosta F, Possin KL, Canu E, Filippi M, Rabinovici GD, et al. Mapping the progression of atrophy in early- and late-onset Alzheimer’s disease. J Alzheimer's Dis : JAD. 2015;46:351–64. https://doi.org/10.3233/jad-142292.CrossRef

37.

Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990;47:753–60.CrossRefPubMed

38.

Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, et al. Age at onset of Alzheimer’s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994;44:1215–20.CrossRefPubMed

39.

Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, et al. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer’s disease a CERAD analysis, part XII. Neurology. 1996;46:136–41.CrossRefPubMed

40.

Cho H, Jeon S, Kang SJ, Lee JM, Lee JH, Kim GH, et al. Longitudinal changes of cortical thickness in early- versus late-onset Alzheimer’s disease. Neurobiol Aging. 2013;34:1921.e9–e15. https://doi.org/10.1016/j.neurobiolaging.2013.01.004.CrossRef

41.

Cho H, Seo SW, Kim JH, Kim C, Ye BS, Kim GH, et al. Changes in subcortical structures in early- versus late-onset Alzheimer’s disease. Neurobiol Aging. 2013;34:1740–7. https://doi.org/10.1016/j.neurobiolaging.2013.01.001.CrossRefPubMed

42.

Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36:811–22.CrossRefPubMedPubMedCentral

43.

Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C] PIB,[18F] FDDNP and [18F] FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990–1000.CrossRefPubMed

44.

Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271–8.CrossRefPubMed

45.

Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology. 1999;52:1158–65.CrossRefPubMed

46.

Bischof GN, Jessen F, Fliessbach K, Dronse J, Hammes J, Neumaier B, et al. Impact of tau and amyloid burden on glucose metabolism in Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3:934–9. https://doi.org/10.1002/acn3.339.CrossRefPubMedPubMedCentral

47.

Cho H, Choi JY, Lee SH, Lee JH, Choi YC, Ryu YH, et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer’s disease. Neurobiol Aging. 2017;53:103–11. https://doi.org/10.1016/j.neurobiolaging.2017.01.024.CrossRefPubMed

48.

Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, et al. In vivo patterns of tau pathology, amyloid-β burden, and neuronal dysfunction in clinical variants of Alzheimer’s disease. J Alzheimers Dis. 2017;55:465–71.CrossRefPubMed

49.

Hanseeuw BJ, Betensky RA, Schultz AP, Papp KV, Mormino EC, Sepulcre J, et al. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81:583–96.CrossRefPubMedPubMedCentral

50.

Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain J Neurol. 2016;139:1551–67. https://doi.org/10.1093/brain/aww027.CrossRef

51.

Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda M, Senjem ML, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer’s disease. Alzheimers Dement. 2018;14(8):1005–14.CrossRefPubMedPubMedCentral

52.

Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785–96.CrossRefPubMedPubMedCentral

53.

Sintini I, Martin PR, Graff-Radford J, Senjem ML, Schwarz CG, Machulda MM, et al. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer’s disease. NeuroImage Clin. 2019;23:101823. https://doi.org/10.1016/j.nicl.2019.101823.CrossRefPubMedPubMedCentral

54.

Franzmeier N, Rubinski A, Neitzel J, Kim Y, Damm A, Na DL, et al. Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease. Brain J Neurol. 2019;142:1093–107. https://doi.org/10.1093/brain/awz026.CrossRef

55.

Ossenkoppele R, Iaccarino L, Schonhaut DR, Brown JA, La Joie R, O'Neil JP, et al. Tau covariance patterns in Alzheimer’s disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage Clin. 2019;23:101848. https://doi.org/10.1016/j.nicl.2019.101848.CrossRefPubMedPubMedCentral

56.

Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42–52. https://doi.org/10.1016/j.neuron.2009.03.024.CrossRefPubMedPubMedCentral

57.

Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216–27. https://doi.org/10.1016/j.neuron.2012.03.004.CrossRefPubMedPubMedCentral

58.

Gour N, Felician O, Didic M, Koric L, Gueriot C, Chanoine V, et al. Functional connectivity changes differ in early and late-onset Alzheimer’s disease. Hum Brain Mapp. 2014;35:2978–94. https://doi.org/10.1002/hbm.22379.CrossRefPubMed

59.

Lehmann M, Madison C, Ghosh PM, Miller ZA, Greicius MD, Kramer JH, et al. Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer’s disease variants. Neurobiol Aging. 2015;36:2678–86. https://doi.org/10.1016/j.neurobiolaging.2015.06.029.CrossRefPubMedPubMedCentral

60.

Whitwell JL, Jones DT, Duffy JR, Strand EA, Machulda MM, Przybelski SA, et al. Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer’s dementia. Neurobiol Aging. 2015;36:1245–52. https://doi.org/10.1016/j.neurobiolaging.2014.12.013.CrossRefPubMed

61.

Lehmann M, Ghosh PM, Madison C, Laforce R, Corbetta-Rastelli C, Weiner MW, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain J Neurol. 2013;136:844–58.CrossRef

62.

van Vliet D, de Vugt ME, Bakker C, Pijnenburg YA, Vernooij-Dassen MJ, Koopmans RT, et al. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychol Med. 2013;43:423–32. https://doi.org/10.1017/s0033291712001122.CrossRefPubMed

63.

Koedam EL, Pijnenburg YA, Deeg DJ, Baak MM, van der Vlies AE, Scheltens P, et al. Early-onset dementia is associated with higher mortality. Dement Geriatr Cogn Disord. 2008;26:147–52. https://doi.org/10.1159/000149585.CrossRefPubMed

Title: Three-year changes of cortical 18F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer’s disease
Authors: Matthieu Vanhoutte
Franck Semah
Xavier Leclerc
Adeline Rollin Sillaire
Alice Jaillard
Grégory Kuchcinski
Xavier Delbeuck
Rachid Fahmi
Florence Pasquier
Renaud Lopes
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04519-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Three-year changes of cortical ¹⁸F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer’s disease

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

EANM Springer Prizes awarded at EANM’ 19 Barcelona

The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases

[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis

Age-associated reorganization of metabolic brain connectivity in Chinese children

Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development

Brain 18FDG-PET pattern in patients with alcohol-related cognitive impairment